Condition: Intestinal Multi-drug Resistant Organism Colonization · Sponsor: Emory University
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection. Limited data from prior studies suggest that MT may be an effective treatment to reduce intestinal MDRO colonization Although shedding of MDROs from patients to their surrounding environment is a recognized pathway of transmission, the potential effect of MT on the transmission of MDRO to other patients in the hospital environment is unclear. This study will test the safety and efficacy of MT for this use in hospitalized patients. This study will also help design larger studies. The MT may help reduce MDROs that colonize the gut. By reducing colonization before infections happen, this could help doctors avoid using "last resort" antibiotics that can have serious side effects like kidney damage. The reduction in MDROs after MT was originally identified in patients treated with MT for recurrent Clostridioides difficile (often called "C. diff") diarrhea. It has been shown that a type of MT called fecal microbiota transplant (FMT) can eliminate both C. difficile and other resistant bacteria.
This description comes directly from the study's public registry record.
Michael Woodworth, MD, MSc · 404-778-1691 · mwoodwo@emory.edu
Ella Wetzel, MS · 770-946-2109 · evwetze@emory.edu
Always discuss trial participation with your own doctor first.
| Emory University Hospital Midtown | Atlanta, Georgia, United States | Recruiting |
| Emory Rehabilitation Hospital | Atlanta, Georgia, United States | Recruiting |
| Emory University Clinical Research Network | Atlanta, Georgia, United States | Recruiting |
| Emory University Hospital (EUH) | Atlanta, Georgia, United States | Recruiting |
| Emory University at Wesley Woods Hospital | Atlanta, Georgia, United States | Recruiting |
| Emory Johns Creek Hospital | Johns Creek, Georgia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05835206